Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | MLYCD | O95822 | 1/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10722330 | 0.89 | MEN1 (0.81) | HDAC6KMT2AMEN1POLBMLYCD | |
| SCHEMBL27383406 | 0.82 | MEN1 (0.71) | HDAC6KMT2AMEN1POLBMLYCD | |
| SCHEMBL22972218 | 0.81 | MEN1 (0.74) | HDAC6KMT2AMEN1POLBMLYCD | |
| SCHEMBL2917118 | 0.80 | TDP1 (0.68) | HDAC6KMT2AMEN1POLBMLYCD | |
| SCHEMBL5967753 | 0.80 | MEN1 (0.71) | HDAC6KMT2AMEN1POLBMLYCD | |
| SCHEMBL29836780 | 0.80 | MEN1 (1.00) | HDAC6KMT2AMEN1POLBMLYCD | |
| SCHEMBL13701732 | 0.80 | RAB9A (0.68) | KDM1ASMN1; SMN2HTT | |
| Methyl Alcohol SCHEMBL11518093 | 0.79 | SMN1; SMN2 (0.72) | HDAC6KMT2AMEN1POLBMLYCD | |
| SCHEMBL1927570 | 0.78 | MEN1 (0.83) | HDAC6KMT2AMEN1POLBMLYCD | |
| SCHEMBL25123079 | 0.78 | SMN1; SMN2 (0.76) | HDAC6KMT2AMEN1POLBMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | HDAC6 3863/4885KMT2A 3792/4885MEN1 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.